Excellence in Clone Development & Stable Cell Line Generation
Your Partner in Advanced Mammalian Expression Systems
At EVIOGEN DISCOVERY, we empower next-generation biotherapeutics with industry-leading expertise in clone development and stable cell line generation. Our state-of-the-art platform accelerates the journey from gene to GMP-ready production cell lines, supporting recombinant proteins, biosimilars, and novel biologics.
Our Core Capabilities
1. Custom Clone Development
- Cell Lines: CHO, HEK293, and other mammalian systems optimized for high yield and human-like post-translational modifications.
- Gene Engineering: Codon-optimized gene synthesis, vector design (CMV, EF1α promoters), and advanced transfection strategies.
- Clone Screening: High-throughput selection based on productivity, glycosylation fidelity, and genetic stability.
- Serum-Free Adaptation: All clones adapted to chemically defined, serum-free suspension culture for seamless scale-up.
2. Stable Cell Line Generation
- Selection & Amplification: MTX or GS selection systems enabling robust, high-expressing clones.
- Scalability: From shake flasks to 2,000L bioreactors for smooth transition to industrial manufacturing.
- Regulatory Compliance: Documentation aligned with WHO, ICH, and CDSCO guidelines.
3. Comprehensive Characterization
- Analytical Excellence: SDS-PAGE, SEC-HPLC, LC-MS/MS, glycan profiling, isoelectric focusing.
- Functional Validation: Enzymatic activity, receptor binding, cell-based uptake assays.
- Stability & Consistency: Long-term stability studies and batch-to-batch consistency.
Why Choose EVIOGEN DISCOVERY?
- Speed & Reliability: Accelerated timelines from DNA to production clone (under 30 weeks).
- Cost-Effective Innovation: Scalable processes reducing manufacturing costs by up to 60%.
- Freedom to Operate: Technologies developed in-house or sourced from public domain ensuring IP safety.
- End-to-End Support: From clone development to comparability studies, assays, and documentation.
Applications
- Biosimilar Development: Rapid generation of reference-matched clones.
- Novel Biologics: Custom cell lines for monoclonal antibodies, fusion proteins, enzymes, etc.
- Rare Disease Therapeutics: Expertise in lysosomal enzymes and glycoproteins for orphan indications.
Ready to Accelerate Your Biologics Program?
Contact our scientific team to discuss your project needs and discover how EVIOGEN DISCOVERY can support robust, scalable, and regulatory-compliant cell line solutions for the future of medicine.
EVIOGEN DISCOVERY - Driving Innovation, Delivering Biotherapeutics.
Target Gene to Master Cell Bank in 6 months
